Cronos Group INC

Cronos Group Inc. has amended its prior filing to confirm that future advisory votes on executive compensation will be held annually, aligning with shareholder preference.

Cronos Group Inc. announced record net revenue, gross profit, and Adjusted EBITDA for Q2 2026, driven by strong performance in Canada, Israel, and Germany, alongside a significant share repurchase program.

Cronos Group reported a 40% year-over-year increase in Q1 2026 net revenue to $45.2 million, driven by strong performance in Israel and Canada, while the acquisition of CanAdelaar B.V. has been extended to September 9, 2026.

Cronos Group announced record net revenue, gross profit, and Adjusted EBITDA for Q4 and full-year 2025, driven by strong brand performance and international market growth.

Cronos Group Inc. is set to acquire CanAdelaar B.V., the largest licensed cannabis producer in the Netherlands' adult-use pilot program, for an upfront cash consideration of €57.5 million plus earnouts.

Cronos Group Inc. announced record consolidated net revenue, gross profit, and Adjusted EBITDA for its third quarter ended September 30, 2025, driven by strong international performance.

Cronos Group Inc. announced a substantial increase in net revenue for the second quarter of 2026, driven by strong performance in Israel and Canada, alongside a return to net income.

Cronos Group Inc. announced its first quarter 2026 financial results, showing a significant increase in net revenue and a return to profitability.

Cronos Group Inc. announced significantly improved financial results for Q3 and the first nine months of 2025, driven by higher gross profit and reduced operating expenses, despite ongoing legal and regulatory challenges.

Cronos Group Inc. reported significant improvements in gross profit and Adjusted EBITDA for Q2 2025, driven by increased sales and production efficiencies, despite a widened net loss due to foreign currency fluctuations.

Cronos Group's Q1 2025 results show a revenue increase driven by international sales and strategic initiatives, alongside a share repurchase authorization.

Cronos Group's Q3 2024 results show a 38% increase in revenue, driven by strong sales in Canada and Israel, alongside strategic moves including the consolidation of Cronos GrowCo.

Cronos Group Inc. reported a significant increase in net revenue and improved Adjusted EBITDA for 2025, driven by international expansion and operational efficiencies, despite a net loss.

Cronos Group's 2024 10-K filing highlights revenue growth, strategic realignments, and key financial metrics amidst a competitive and evolving cannabis market.

Cronos Group Inc. has amended and restated an executive employment agreement and filed its annual report on Form 10-K, detailing financial results and strategic initiatives.

Murray R Garnick, a Director of Cronos Group Inc., received 48,860 shares of common stock on August 6, 2026.

James Daniel Rudyk, a Director of Cronos Group Inc., received 48,860 shares of common stock on August 6, 2026.

Jason Marc Adler, a Director of Cronos Group Inc., received 48,860 shares of common stock on August 6, 2026.

Terrence Doucet, General Counsel and Corporate Secretary of Cronos Group Inc., reported transactions involving restricted stock units and common shares.

Adam Wagner, an officer at Cronos Group Inc., reported a transaction involving the acquisition of 10,367 common shares via restricted stock units.

Shannon Buggy, Senior Vice President at Cronos Group Inc., reported a transaction involving restricted stock units and common shares.

Cronos Group Inc. has scheduled its 2026 Annual Meeting of Shareholders for June 18, 2026, to be held in a virtual-only format.

Cronos Group Inc. has filed a definitive proxy statement with the SEC, outlining matters for shareholder consideration.

Cronos Group Inc. announces its 2025 annual meeting of shareholders to be held virtually on June 20, 2025, featuring proposals for director elections, executive compensation approval, and auditor appointment.

Cronos Group has appointed Davidson & Company as its new independent auditor after KPMG decided to cease providing audit services to cannabis companies.

Cronos Group Inc. has filed a definitive proxy statement with the SEC, outlining matters for shareholder consideration.

Cronos Group sets date for its annual shareholder meeting and discloses that KPMG will not stand for reappointment as auditor due to its exit from cannabis industry audits.